Therefore, a mAb that is monospecific for HLA-E and at the same time capable of binding to the amino acid ligands of CD94/NKG2A on the HLA-E molecule will be potentially useful to restore cytotoxic killing of tumor cells as well as for the specific recognition of tumor cells expressing HLA-E on the cell surface, potentially being amenable to such therapy. This evidence concerns the gene KLRD1 and neoplasm.